JAZZ Venture Partners is a San Francisco-based venture capital firm founded in 2015 with approximately $287M AUM. It is one of the most explicitly neuroscience-oriented VCs outside dedicated neurotech funds, investing in companies that leverage brain science to improve human health, performance, and wellbeing.

The firm's team includes practicing neuroscientists and neurosurgeons, including UCSF neurology professor Adam Gazzaley as a Venture Partner. Portfolio companies include Cadence Neuroscience (neuromodulation for drug-resistant epilepsy, JAZZ was lead Series A investor), Magnus Medical (TMS therapy for depression), Halo Neuroscience (neurostimulation for performance), Akili Interactive (digital neurotherapeutics, IPO via SPAC), Blue Note Therapeutics (digital therapeutics for cancer distress), and Woebot (AI mental health). JAZZ invests from seed to Series B and focuses on the US market.